China Releases Draft List of Second Batch of Encouraged Generic Medicines

by Grace Wang Mar 08, 2021
China National Health Commission (NHC) published the Draft List of Second Batch of Encouraged Generic Medicines, involving 19 drugs that will be off-patent in 2021 or 2022.

On Dec. 30, 2020, China National Health Commission (NHC) issued the Draft List of Second Batch of 19 Generic Medicines, encouraging pharmaceutical firms to develop and produce them. Medicines for chronic obstructive pulmonary disease and asthma are included in the list.

The 19 medicines were proposed by experts from the NHC, the Ministry of Science and Technology, the Ministry of Industry and Information Technology, the National Medical Products Administration and the National Intellectual Property Administration. The patents of these drugs will soon be expired in 2021 or 2020, with no fresh applications for registration.1

Details on the Draft List of Second Batch of Encouraged Generic Medicines

SN

Drug Name

Dosage Form

Strength

1

Arformoterol

Inhalation Solutions

2ml: 15μg

2

Fluticasone Furoate and Vilanterol Trifenatate

Powder for Inhalation

0.1mg Fluticasone, 25μg Vilanterol

3

Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate

Powder for Inhalation

0.1mg Fluticasone, 62.5μg Umetium Bromide, 25μg Vilanterol, 0.2mg Fluticasone, 62.5μg Umetium Bromide, 25g Vilanterol

4

Clevidipine

Emulsions for Injection

50ml: 25mg, 100ml: 50mg

5

Obeticholic acid

Tablets

5mg

6

Plecanatide

Tablets

3mg

7

Mirabegron

Sustained-Release Tablets

25mg, 50mg

8

Elagolix

Tablets

150mg, 200mg

9

Eliglustat

Capsules

84mg

10

Macimorelin

Oral Solutions

120ml: 60mg

11

Eslicarbazepine

Tablets

200mg, 400mg

12

Perampanel

Tablets

2mg, 4mg

Oral Suspensions

0.5mg/ml

13

Brivaracetam

Tablets

10mg, 25mg, 50mg

Oral Solutions

10mg/ml

Injections

5ml: 50mg

14

Desvenlafaxine

Sustained-Release Tablets

25mg, 50mg, 100mg

15

Tasimelteon

Capsules

20mg

16

Tapentadol

Sustained-Release Tablets

50mg, 100mg

17

Brimonidine Tartrate and Timolol Maleate

Eye Drops

0.2% Brimonidine Tartrate, 0.5% Timolol Maleate

18

Cabazitaxel

Injections

1.5ml: 60mg

19

Olaparib

Tablets

150mg

China has already promulgated a series of policies to encourage the production of generic drugs. In April 2018, the General Office of State Council announced Opinions Concerning Reforms of Policies to Improve the Supply and Utilization of Generics, encouraging the manufacture of generic drugs that are clinically necessary, have definite efficacy and are in short supply. It also advocated the manufacture of generic drugs for the prevention and treatment of major infectious diseases and rare diseases, for the treatment of public health emergencies, for children's use, and for which no application for registration has been filed one year before the patent expires.2

In December of the same year, twelve departments, including NHC, issued the Work Plan on Accelerating the Implementation of Policies on the Supply and Utilization of Generic Drugs, explicitly promising to publish a list of drugs that encourage copycats by the end of each year starting in 2020, and encouraging the research on key chemical and biological drugs in the list to be included in the relevant national science and technology plan.3

In Oct. 2019, NHC and other departments published the List of First Batch of 33 Encouraged Generic Medicines and required relevant departments to support these medicines in clinical trials, critical generic technology research and priority review and approval in accordance with relevant regulations.4

Grace Wang
ChemLinked Regulatory Analyst & Editor
+ FOLLOW
Copyright: unless otherwise stated all contents of this website are ©2024 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com
You May Also Like
Most Popular